Biocon has reported a 35.39 per cent decline in its consolidated net profit at Rs 108.4 crore for the quarter ended June 30, 2021, mainly on account of its share of loss in associate startup entity Bicara Therapeutics Inc. The company had posted a net profit of Rs 167.8 crore for the corresponding period of the previous fiscal, Biocon said in a late-night filing on Thursday.

Consolidated revenue of the company stood at Rs 1,807.8 crore for the quarter under consideration. It was Rs 1,712.1 crore for the same period a year ago, it added.

“Consolidated revenues, at Rs 1,808 crore, saw a muted growth on account of COVID-related operational challenges at Biocon’s API facilities, both in Bengaluru and Hyderabad,” Biocon Executive Chairperson Kiran Mazumdar-Shaw said.

• Transrail Lighting Bags Rs 459 Cr MENA Transmission Orders
• Kotak Mahindra Bank Hikes DCC Fee to 3.5% from August
• Jubilant Pharmova Arm Gets USFDA Nod for Antacid Drug
• TVS Motor Jumps 3.75% as NTORQ 125 Gets New Colours
• Fortis Healthcare Falls 2.25% as Delhi Govt Orders Probe

Q1FY22 P&L was also impacted by a share of loss in its Boston-based associate start-up entity, Bicara Therapeutics Inc, she added.’

Stock Covered in the news

Biocon Ltd-View Detailed Analysis